State Street Corp Landos Biopharma, Inc. Transaction History

State Street Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.6 - $1.5 $50,997 - $127,494	-84,996 Reduced 77.13%	25,200 $18,000
Q1 2022 May 16, 2022	BUY	$1.44 - $5.22 $3,744 - $13,572	2,600 Added 2.42%	110,196 $163,000
Q4 2021 Feb 14, 2022	BUY	$4.7 - $15.0 $141 - $450	30 Added 0.03%	107,596 $516,000
Q3 2021 Nov 15, 2021	BUY	$9.77 - $15.77 $148,494 - $239,688	15,199 Added 16.46%	107,566 $1.57 Million
Q2 2021 Aug 16, 2021	BUY	$9.26 - $12.53 $400,698 - $542,198	43,272 Added 88.14%	92,367 $1.07 Million
Q1 2021 May 17, 2021	BUY	$9.47 - $16.26 $464,929 - $798,284	49,095 New	49,095 $473,000

Ticker LABP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,254,900
Description
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of u...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.